The Food and Drug Administration (FDA) have approved a new and innovative Bovine Respiratory Disease (BRD) treatment. This new treatment is designed for the treatment of groups of cattle in the early stages of Bovine Respiratory Disease (BRD) outbreak that provides 14 days of sustained in-feed therapy. Pulmotil is approved for the control of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10 percent of the animals in the group. “This approval brings cattle veterinarians and producers a truly new management tool for controlling BRD,” says Jeff Simmons, president, Elanco. Read more ...
This blog is written by Martin Little, The Global Miller, published and supported by the GFMT Magazine and the International Milling Directory from Perendale Publishers.
This blog is written by Martin Little, The Global Miller, published and supported by the GFMT Magazine and the International Milling Directory from Perendale Publishers.
No comments:
Post a Comment